mefloquine-sulfadoxine-pyrimethamine has been researched along with chloroquine in 10 studies
*Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses. [MeSH]
*Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses. [MeSH]
| Studies (mefloquine-sulfadoxine-pyrimethamine) | Trials (mefloquine-sulfadoxine-pyrimethamine) | Recent Studies (post-2010) (mefloquine-sulfadoxine-pyrimethamine) | Studies (chloroquine) | Trials (chloroquine) | Recent Studies (post-2010) (chloroquine) |
|---|---|---|---|---|---|
| 43 | 20 | 0 | 16,405 | 763 | 4,029 |
| Protein | Taxonomy | mefloquine-sulfadoxine-pyrimethamine (IC50) | chloroquine (IC50) |
|---|---|---|---|
| glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase | Plasmodium berghei | 43 | |
| Spike glycoprotein | Betacoronavirus England 1 | 5.47 | |
| Replicase polyprotein 1ab | Betacoronavirus England 1 | 5.47 | |
| Transmembrane protease serine 2 | Homo sapiens (human) | 5.47 | |
| Dihydrofolate reductase | Bos taurus (cattle) | 0.0301 | |
| Amyloid-beta precursor protein | Homo sapiens (human) | 7 | |
| Histidine-rich protein PFHRP-II | Plasmodium falciparum (malaria parasite P. falciparum) | 0.2383 | |
| Procathepsin L | Homo sapiens (human) | 5.47 | |
| Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
| Replicase polyprotein 1ab | Human coronavirus 229E | 5.47 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
| Spike glycoprotein | Severe acute respiratory syndrome coronavirus 2 | 3.58 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 6.375 | |
| Ribosyldihydronicotinamide dehydrogenase [quinone] | Homo sapiens (human) | 1.5 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.27 | |
| Beta-secretase 1 | Homo sapiens (human) | 7 | |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 2.503 | |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | 6.235 | |
| Cysteine proteinase falcipain 2a | Plasmodium falciparum (malaria parasite P. falciparum) | 0.02 | |
| Cysteine proteinase falcipain 2a | Plasmodium falciparum (malaria parasite P. falciparum) | 0.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (30.00) | 18.7374 |
| 1990's | 7 (70.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bunnag, D; Chindanond, D; Chittamas, S; Fernex, M; Harinasuta, T; Kristiansen, S; Malikul, S; Mittelholzer, ML; Sturchler, D | 1 |
| Adio, RA; Dickschat, U; Mittelholzer, ML; Reber-Liske, R; Salako, LA; Sowunmi, A; Stürchler, D; Walker, O | 1 |
| Bunnag, D; Chitamas, S; Harinasuta, T; Karbwang, J; Viravan, C | 1 |
| Eberlé, F; Gazin, P; Gelas, H; Hengy, C; Jambou, R; Kouka-Bemba, D | 1 |
| Aina Adio, R; Fadeke Aderounmu, A; Laoye, AJ; Modupe Makinde, J; Salako, LA | 1 |
| Kollaritsch, H; Kollaritsch, R; Kremsner, P; Leimer, R; Mailer, H; Stemberger, H; Wiedermann, G | 1 |
| Aderounmu, AF; Adio, RA; Laoye, JO; Makinde, JM; Salako, LA | 1 |
| Chatnugrob, P; Eamsila, C; Lasserre, R; Mittelholzer, ML; Nopavong Na Ayuthya, A; Singharaj, P; Stürchler, D; Webster, HK; Yooyen, P | 1 |
| Schubarth, P | 1 |
| Alaribe, AA; Chukwuani, CM; Ekanem, OJ; Ezedinachi, EN; Haller, L; Meremikwu, MM; Ojar, EA; Umotong, AB | 1 |
1 review(s) available for mefloquine-sulfadoxine-pyrimethamine and chloroquine
| Article | Year |
|---|---|
[Malaria: the most important emergency in subjects returning from the tropics].
Topics: Animals; Antimalarials; Chloroquine; Drug Combinations; Emergencies; Humans; Malaria; Malaria, Falciparum; Mefloquine; Plasmodium; Pyrimethamine; Quinidine; Quinine; Sulfadoxine | 1993 |
7 trial(s) available for mefloquine-sulfadoxine-pyrimethamine and chloroquine
| Article | Year |
|---|---|
Fansimef for prophylaxis of malaria: a double-blind randomized placebo controlled trial.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Double-Blind Method; Drug Combinations; Humans; Incidence; Malaria, Falciparum; Male; Mefloquine; Middle Aged; Pyrimethamine; Sulfadoxine; Treatment Outcome | 1992 |
Mefloquine-sulphadoxine-pyrimethamine (Fansimef, Roche) in the prophylaxis of Plasmodium falciparum malaria: a double-blind, comparative, placebo-controlled study.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Double-Blind Method; Drug Combinations; Humans; Malaria, Falciparum; Male; Mefloquine; Middle Aged; Pyrimethamine; Sulfadoxine | 1992 |
Clinical trials of mefloquine with tetracycline.
Topics: Acute Disease; Adolescent; Adult; Chloroquine; Drug Combinations; Drug Resistance; Drug Therapy, Combination; Humans; Malaria, Falciparum; Male; Mefloquine; Middle Aged; Prospective Studies; Pyrimethamine; Sulfadoxine; Tetracycline | 1992 |
Comparison of the susceptibility of falciparum malaria to mefloquine-sulphadoxine-pyrimethamine and chloroquine in Nigeria.
Topics: Animals; Antimalarials; Child; Chloroquine; Clinical Trials as Topic; Drug Administration Schedule; Drug Combinations; Drug Resistance; Female; Humans; Malaria; Male; Mefloquine; Nigeria; Plasmodium falciparum; Pyrimethamine; Quinolines; Random Allocation; Sulfadoxine; Sulfanilamides | 1988 |
Tolerability of long-term malaria prophylaxis with the combination mefloquine + sulfadoxine + pyrimethamine (Fansimef): results of a double blind field trial versus chloroquine in Nigeria.
Topics: Adolescent; Adult; Animals; Antimalarials; Aspartate Aminotransferases; Blood Cell Count; Child; Chloroquine; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; Humans; Malaria; Male; Mefloquine; Middle Aged; Nigeria; Plasmodium falciparum; Pyrimethamine; Quinolines; Random Allocation; Sulfadoxine; Sulfanilamides | 1988 |
Sensitivity of Plasmodium falciparum to mefloquine-sulphadoxine-pyrimethamine (Fansimef) in vivo and to mefloquine alone in vitro in Nigeria.
Topics: Animals; Antimalarials; Child; Chloroquine; Drug Combinations; Drug Evaluation; Drug Resistance; Female; Humans; Malaria; Male; Mefloquine; Nigeria; Plasmodium falciparum; Pyrimethamine; Quinolines; Random Allocation; Sulfadoxine; Sulfanilamides | 1988 |
Prevention of Plasmodium falciparum malaria by Fansimef and Lariam in the northeastern part of Thailand.
Topics: Adult; Animals; Antibodies, Protozoan; Blood; Chloroquine; Drug Combinations; Humans; Malaria, Falciparum; Male; Mefloquine; Military Personnel; Plasmodium falciparum; Pyrimethamine; Sulfadoxine; Thailand | 1993 |
2 other study(ies) available for mefloquine-sulfadoxine-pyrimethamine and chloroquine
| Article | Year |
|---|---|
[Uncomplicated malaria attack in an area with high resistance to chloroquine. 3. The use of second-choice oral drug treatment].
Topics: Adolescent; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Female; Humans; Infant; Malaria; Male; Mefloquine; Plasmodium falciparum; Pyrimethamine; Sulfadoxine; Sulfanilamides | 1990 |
Efficacy and tolerability of a low-dose mefloquine-sulfadoxine-pyrimethamine combination compared with chloroquine in the treatment of acute malaria infection in a population with multiple drug-resistant Plasmodium falciparum.
Topics: Adolescent; Adult; Animals; Antimalarials; Blood; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance, Multiple; Female; Humans; Infant; Malaria, Falciparum; Male; Mefloquine; Middle Aged; Nigeria; Plasmodium falciparum; Prospective Studies; Pyrimethamine; Random Allocation; Sulfadoxine | 1999 |